Chromatin analysis of multiple myeloma cells following CBP/p300 inhibition and degradation (ChIP-Seq)
Ontology highlight
ABSTRACT:
ORGANISM(S): Homo sapiens
PROVIDER: GSE160335 | GEO | 2020/12/31
REPOSITORIES: GEO
Similar Datasets
Project description:We performed RNA-seq on MM.1S cells treated with A-485, GNE-781, and the combination of both, or with dCBP-1.
2020-12-31 | GSE160336 | GEO
Project description:We performed ATAC-seq on MM.1S cells treated with A-485, GNE-781, and the combination of both, or with dCBP-1.
2020-12-31 | GSE160333 | GEO
Project description:Comparison of CBP/p300 gene knock-out, bromodomain inhibitor, and acetyltransferase inhibitors Cmpd-R and A-485 in the same cell line (MEF).
2018-06-13 | GSE92613 | GEO
Project description:The dynamic and reversible acetylation of proteins catalyzed by histone acetyltransferases (HATs) and histone deacetylases (HDACs) was discovered more than 2 decades ago and the enzymatic function of these enzymes are established as a major epigenetic regulatory mechanism of gene transcription. Thus, these epigenetic modifiers are involved in multiple diseases and represent attractive targets for therapeutic intervention. While HDAC inhibitors have been developed and approved by the FDA to treat certain cancers, progress on the development of drug-like HAT inhibitors has lagged. The HAT paralogs p300 and CBP (here called p300/CBP) are key transcriptional co-activators that are essential for a multitude of cellular processes and also implicated in human pathological conditions, including cancer. Current p300/CBP HAT domain inhibitors including natural products and bisubstrate analogs such as Lys-CoA either lack potency and selectivity or suffer from poor cellular permeability. C646 is widely utilized as a tool to inhibit p300/CBP HAT activity, but its off-target activity and reactivity may limit its cellular specificity. Here, we describe A-485 as a potent, selective and drug-like p300/CBP catalytic inhibitor. We show the first high resolution (1.95Å) co-crystal structure of a pharmacologically active small molecule (A-485) bound to the catalytic active site of p300 HAT domain and demonstrate that A-485 is an acetyl-CoA competitive inhibitor of p300/CBP. A-485 selectively inhibited proliferation across lineage-specific tumor types, including several hematological malignancies and androgen receptor-positive prostate cancer. A-485 robustly inhibited the androgen receptor transcriptional program in both androgen sensitive and castrate resistant prostate cancer and inhibited tumor growth in a castration resistant xenograft model. These results demonstrate the feasibility of selectively drugging the catalytic activity of histone acetyltransferases, provide the framework for delineating the enzymatic functions of HATs, and pave the way for the development of novel therapeutics targeting HAT activity.
2017-09-27 | GSE94580 | GEO
Project description:Targeting the p300/CBP axis in lethal prostate cancer.
| PRJEB41478 | ENA
Project description:This is a dataset generated by the Drosophila Regulatory Elements modENCODE Project led by Kevin P. White at the University of Chicago. It contains ChIP-chip data on Agilent 244K dual-color arrays for antibody: CBP/p300 at 12 different time-points of Drosophila development. Current Dataset: [GSM386269..GSM386277]: ChIP-chip of CBP in Drosophila embryos at 4-8 hours of development [GSM386279..GSM386287]: ChIP-chip of CBP in Drosophila embryos at 20-24 hours of development [GSM418309..GSM418317]: ChIP-chip of CBP in adult female Drosophila [GSM418318..GSM418326]: ChIP-chip of CBP in adult male Drosophila [GSM418335..GSM418343]: ChIP-chip of CBP in Drosophila embryos at 16-20 hours of development [GSM418454..GSM418462]: ChIP-chip of CBP in Drosophila L3 larvae [GSM418463..GSM418471]: ChIP-chip of CBP in Drosophila pupae [GSM442425..GSM442433]: ChIP-chip of CBP in Drosophila embryos at 0-4 hours of development [GSM443119..GSM443127]: ChIP-chip of CBP in Drosophila L1 larvae For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODEDataReleasePolicyFinal2008.pdf For each combination of time-point and antibody, triplicate ChIP experiments have been performed and hybridized on Agilent 244K arrays. 3 arrays per genome have been used so that each time-point is a set of 9 tiling arrays.
2010-06-21 | E-GEOD-15427 | biostudies-arrayexpress
Project description:This is a dataset generated by the Drosophila Regulatory Elements modENCODE Project led by Kevin P. White at the University of Chicago. It contains ChIP-chip data on Agilent 244K dual-color arrays for antibody: CBP/p300 at 12 different time-points of Drosophila development. Current Dataset: [GSM386269..GSM386277]: ChIP-chip of CBP in Drosophila embryos at 4-8 hours of development [GSM386279..GSM386287]: ChIP-chip of CBP in Drosophila embryos at 20-24 hours of development [GSM418309..GSM418317]: ChIP-chip of CBP in adult female Drosophila [GSM418318..GSM418326]: ChIP-chip of CBP in adult male Drosophila [GSM418335..GSM418343]: ChIP-chip of CBP in Drosophila embryos at 16-20 hours of development [GSM418454..GSM418462]: ChIP-chip of CBP in Drosophila L3 larvae [GSM418463..GSM418471]: ChIP-chip of CBP in Drosophila pupae [GSM442425..GSM442433]: ChIP-chip of CBP in Drosophila embryos at 0-4 hours of development [GSM443119..GSM443127]: ChIP-chip of CBP in Drosophila L1 larvae For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODEDataReleasePolicyFinal2008.pdf
2009-03-28 | GSE15427 | GEO
Project description:A recently identified pediatric subtype of undifferentiated round cell sarcoma that is driven by fusion between the cell cycle regulator and transcriptional repressor, capicula (CIC) and the transcriptional activator, DUX4 has been identified based on its histology, clinical differences, and aggressiveness. Because CIC-DUX4 acquires the p300-interacting activation domain of DUX4, we hypothesized that its transcriptional activation potential, and thus the oncogenicity of CIC-DUX4, would require p300 or its homologues, CBP. Recently, a new class of histone acetyltransferase inhibitors with high selectivity for p300 and CBP has been described, and two compounds, A-485, and iP300w, have been shown to inhibit p300 and CBP both in vitro and in vivo with iP300w having the ability to reverse gene expression changes caused by DUX4. If this hypothesis is correct, iP300w should potently counteract the CIC-DUX4 gene expression program and might be a particularly effective therapy for CDS. In this study, we confirm this hypothesis, demonstrating that CIC-DUX4 requires p300/CBP for its activity. We also demonstrate that CIC-DUX4 induces a global increase in H3 acetylation, like DUX4, which is reversible with iP300w treatment. We find that CIC-DUX4 activity is potently blocked by iP300w, and that this compound has potent activity against CDS cell lines and in an in vivo cancer xenograft assay.
2021-10-21 | GSE165729 | GEO